Clinical advantages of reduced expiratory positive airway pressure setting in adaptive servo-ventilation therapy.

IF 1.4 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Heart and Vessels Pub Date : 2024-09-22 DOI:10.1007/s00380-024-02457-8
Teruhiko Imamura, Yoshihiro Fukumoto, Hitoshi Adachi, Shin-Ichi Momomura, Yoshio Yasumura, Takayuki Hidaka, Takatoshi Kasai, Koichiro Kinugawa, Yasuki Kihara
{"title":"Clinical advantages of reduced expiratory positive airway pressure setting in adaptive servo-ventilation therapy.","authors":"Teruhiko Imamura, Yoshihiro Fukumoto, Hitoshi Adachi, Shin-Ichi Momomura, Yoshio Yasumura, Takayuki Hidaka, Takatoshi Kasai, Koichiro Kinugawa, Yasuki Kihara","doi":"10.1007/s00380-024-02457-8","DOIUrl":null,"url":null,"abstract":"<p><p>The clinical ramifications of adaptive servo-ventilation (ASV) therapy have stirred debate within the medical community. Given the potential detrimental effect of elevated expiratory positive airway pressure (EPAP) on cardiac output, we hypothesized that relatively lower EPAP may be recommended for successful ASV therapy. In-hospital patients with congestive heart failure refractory to medical therapy were included in the prospective cohort study of ASV therapy on prognosis in repeatedly hospitalized patients with chronic heart failure: longitudinal observational study of effects on readmission and mortality (SAVIOR-L) study. Assignment to either the ASV treatment group or the medical management group was at the discretion of the attending physicians. For the purposes of this retrospective study, our focus remained solely on the ASV cohort. We conducted an extensive analysis to elucidate the influence of lower EPAP settings on midterm mortality. A total of 108 patients were included. The median age was 74 years, and 83 (77%) patients were male. The median EPAP setting employed was 4 cmH<sub>2</sub>O, with 60 patients subjected to EPAP levels below 5 cmH<sub>2</sub>O. There were no significant differences in the baseline characteristics between the lower and higher EPAP groups, which were divided at the EPAP cutoff of 4.5 cmH<sub>2</sub>O (p > 0.05 for all). A trend toward reduced mortality emerged among patients with EPAP settings below 5 cmH<sub>2</sub>O, exhibiting a hazard ratio of 0.48 (95% confidence interval 0.22-1.07, p = 0.072) after adjusting for potential confounding factors: 2-year mortality 26% vs. 38%; p = 0.095. Heart failure readmission rates were not significantly different between the two groups (p = 0.61). The adoption of relatively lower EPAP settings during ASV therapy may be advisable. Such an approach has the potential to ameliorate mortality rates while concurrently maintaining heart failure recurrence rates at levels commensurate with those with default EPAP settings.</p>","PeriodicalId":12940,"journal":{"name":"Heart and Vessels","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart and Vessels","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00380-024-02457-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

The clinical ramifications of adaptive servo-ventilation (ASV) therapy have stirred debate within the medical community. Given the potential detrimental effect of elevated expiratory positive airway pressure (EPAP) on cardiac output, we hypothesized that relatively lower EPAP may be recommended for successful ASV therapy. In-hospital patients with congestive heart failure refractory to medical therapy were included in the prospective cohort study of ASV therapy on prognosis in repeatedly hospitalized patients with chronic heart failure: longitudinal observational study of effects on readmission and mortality (SAVIOR-L) study. Assignment to either the ASV treatment group or the medical management group was at the discretion of the attending physicians. For the purposes of this retrospective study, our focus remained solely on the ASV cohort. We conducted an extensive analysis to elucidate the influence of lower EPAP settings on midterm mortality. A total of 108 patients were included. The median age was 74 years, and 83 (77%) patients were male. The median EPAP setting employed was 4 cmH2O, with 60 patients subjected to EPAP levels below 5 cmH2O. There were no significant differences in the baseline characteristics between the lower and higher EPAP groups, which were divided at the EPAP cutoff of 4.5 cmH2O (p > 0.05 for all). A trend toward reduced mortality emerged among patients with EPAP settings below 5 cmH2O, exhibiting a hazard ratio of 0.48 (95% confidence interval 0.22-1.07, p = 0.072) after adjusting for potential confounding factors: 2-year mortality 26% vs. 38%; p = 0.095. Heart failure readmission rates were not significantly different between the two groups (p = 0.61). The adoption of relatively lower EPAP settings during ASV therapy may be advisable. Such an approach has the potential to ameliorate mortality rates while concurrently maintaining heart failure recurrence rates at levels commensurate with those with default EPAP settings.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在自适应伺服通气疗法中降低呼气正压设置的临床优势。
自适应伺服通气疗法(ASV)的临床影响在医学界引起了争论。鉴于呼气正压(EPAP)升高可能对心输出量产生不利影响,我们推测,要想成功进行 ASV 治疗,建议采用相对较低的 EPAP。反复住院的慢性心力衰竭患者接受 ASV 治疗对预后的影响的前瞻性队列研究:对再入院和死亡率影响的纵向观察研究(SAVIOR-L)。ASV治疗组或医疗管理组的分配由主治医生决定。在这项回顾性研究中,我们只关注 ASV 治疗组。我们进行了广泛的分析,以阐明较低 EPAP 设置对中期死亡率的影响。共纳入了 108 名患者。中位年龄为 74 岁,83 名(77%)患者为男性。采用的 EPAP 设置中位数为 4 cmH2O,其中 60 名患者的 EPAP 水平低于 5 cmH2O。以 EPAP 4.5 cmH2O 为界限划分的 EPAP 较低组和较高组在基线特征方面没有明显差异(所有差异的 p > 0.05)。EPAP设置低于5 cmH2O的患者死亡率呈下降趋势,调整潜在混杂因素后,其危险比为0.48(95% 置信区间为0.22-1.07,P = 0.072):2年死亡率为26% vs. 38%; p = 0.095。两组心衰再入院率无明显差异(p = 0.61)。在 ASV 治疗期间采用相对较低的 EPAP 设置可能是可取的。这种方法有可能降低死亡率,同时将心衰复发率维持在与默认 EPAP 设置相当的水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Heart and Vessels
Heart and Vessels 医学-外周血管病
CiteScore
3.10
自引率
13.30%
发文量
211
审稿时长
2 months
期刊介绍: Heart and Vessels is an English-language journal that provides a forum of original ideas, excellent methods, and fascinating techniques on cardiovascular disease fields. All papers submitted for publication are evaluated only with regard to scientific quality and relevance to the heart and vessels. Contributions from those engaged in practical medicine, as well as from those involved in basic research, are welcomed.
期刊最新文献
Association between high plasma levels of legumain and cardiovascular events in patients undergoing coronary angiography. Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years. Plasma microRNA-143 and microRNA-145 levels are elevated in patients with left ventricular dysfunction. Bilateral pulmonary artery banding facilitates the systemic ventricular outflow tract growth for biventricular and univentricular repair candidates of complex arch anomaly. Evaluation of novel indices of walking performance taking oxygen desaturation into account during six-minute walk test in cardiovascular disease patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1